课题基金 / 基金详情

BR96 DOXORUBICIN CONJUGATE VS DOXORUBICIN IN METASTATIC BREAST CANCER

BR96 DOXORUBICIN CONJUGATE VS DOXORUBICIN IN METASTATIC BREAST CANCER
BR96 多柔比星结合物与多柔比星在转移性乳腺癌中的比较
批准号：
6274063
负责人：
MANSOOR N SALEH
金额：
$2.59万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-01-26 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274063
关键词：
breast neoplasms clinical research combination cancer therapy doxorubicin drug screening /evaluation female human subject human therapy evaluation immunoconjugates metastasis monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy pharmacokinetics women's health

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项II期临床试验， 或者作为与单克隆抗Lewis（γ） 抗体BR 96或作为静脉内单次注射从头给药 化疗 BR 96多柔比星已被证明是良好的耐受性， 之前的第一阶段研究和动物研究已经证明了戏剧性的 在乳腺肿瘤异种移植物中的抗肿瘤作用。 该研究旨在比较 BR 96-阿霉素将细胞毒性水平的阿霉素递送至 与单药阿霉素相比， 相应的临床结果。
英文摘要
This is a phase II trial comparing delivery of the agent doxorubicin either as an immunoconjugate linked to the monoclonal anti-Lewis(y) antibody BR96 or delivered as intravenous single injection of the de novo chemotherapy. BR96 doxorubicin has been shown to be well tolerated in a previous phase I study, and animal studies have demonstrated dramatic anti-tumor effects in breast tumor xenograft. The study aims to compare ability of BR96-doxorubicin to deliver cytoxic levels of doxorubicin to the tumor, as compared to single-agent doxorubicin, and assess the corresponding clinical outcome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金